Mostrando 10 resultados de: 15
Publisher
Clinical Cancer Research(3)
Nature(2)
Annual Review of Medicine(1)
Cell(1)
Cell Chemical Biology(1)
Área temáticas
Enfermedades(12)
Farmacología y terapéutica(7)
Fisiología humana(2)
Bioquímica(1)
Química analítica(1)
Área de conocimiento
Cáncer(10)
Bioquímica(4)
Farmacología(4)
Descubrimiento de fármacos(2)
Medicamento(1)
Origen
scopus(15)
Androstenedione is the preferred androgen source in hormone refractory prostate cancer Letter
OtherAbstract:Palabras claves:Autores:Richard J. Auchus, Sharifi N.Fuentes:scopus"Getting from here to there"-mechanisms and limitations to the activation of the androgen receptor in castration-resistant prostate cancer
ReviewAbstract: Despite the clinical regression that typifies the initial response of advanced prostate cancer to goPalabras claves:androgen receptor, Androgens, Steroid metabolismAutores:McPhaul M., Richard J. Auchus, Sharifi N.Fuentes:scopus3β-hydroxysteroid dehydrogenase is a possible pharmacological target in the treatment of castration-resistant prostate cancer
ArticleAbstract: Prostate cancer usually responds to androgen deprivation therapy, although the response in metastatiPalabras claves:Autores:Evaul K., Li R., Papari-Zareei M., Richard J. Auchus, Sharifi N.Fuentes:scopusDevelopment and validation of a novel LC–MS/MS method for simultaneous determination of abiraterone and its seven steroidal metabolites in human serum: Innovation in separation of diastereoisomers without use of a chiral column
ArticleAbstract: Abiraterone acetate (AA), the prodrug of abiraterone, is FDA-approved for the treatment of castratioPalabras claves:abiraterone, LC–MS/MS, Metabolites, Method validation, Prostate cancerAutores:Alyamani M., Anderson D., Li Z., Richard J. Auchus, Sharifi N., Upadhyay S.K.Fuentes:scopusConversion of abiraterone to D4A drives anti-tumour activity in prostate cancer
ArticleAbstract: Prostate cancer resistance to castration occurs because tumours acquire the metabolic capability ofPalabras claves:Autores:Alyamani M., Bishop A., Bunch D., Dreicer R., Garcia J., Li Z., Liu J., Richard J. Auchus, Sharifi N., Upadhyay S.K.Fuentes:scopusAbiraterone acetate treatment lowers 11-oxygenated androgens
ArticleAbstract: Context: The human adrenal is the dominant source of androgens in castration-resistant prostate cancPalabras claves:Autores:Alyamani M., O'Day P.J., Richard J. Auchus, Sharifi N., Wright C.Fuentes:scopusAbiraterone inhibits 3β-hydroxysteroid dehydrogenase: A rationale for increasing drug exposure in castration-resistant prostate cancer
ArticleAbstract: Purpose: Treatment with abiraterone (abi) acetate prolongs survival in castration-resistant prostatePalabras claves:Autores:Chang K.H., Evaul K., Li R., Liu J., Richard J. Auchus, Sharifi N., Sharma K.K., Yoshimoto J.A.Fuentes:scopusDihydrotestosterone synthesis bypasses testosterone to drive castration-resistant prostate cancer
ArticleAbstract: In the majority of cases, advanced prostate cancer responds initially to androgen deprivation therapPalabras claves:5-alpha-androstanedione, Abiraterone acetate, Hormonal therapy, Hormone resistance, Tumor metabolismAutores:Chang K.H., Li R., Papari-Zareei M., Richard J. Auchus, Sharifi N., Watumull L., Zhao Y.Fuentes:scopusMolecular pathways: Inhibiting steroid biosynthesis in prostate cancer
ReviewAbstract: A significant proportion of castration-resistant prostate cancers (CRPC) remains driven by ligand acPalabras claves:Autores:Attard G., Ferraldeschi R., Richard J. Auchus, Sharifi N.Fuentes:scopusHSD3B1(1245A>C) variant regulates dueling abiraterone metabolite effects in prostate cancer
ArticleAbstract: BACKGROUND. A common germline variant in HSD3B1(1245A>C) encodes for a hyperactive 3β-hydroxysteroidPalabras claves:Autores:Almassi N., Alyamani M., Berk M.P., Chien C., Emamekhoo H., Figg W.D., Garcia J., Grivas P.D., Hu B., Hwang T.H., Koshkin V.S., Mendiratta P., Park S., Peer C.J., Richard J. Auchus, Rini B., Sharifi N., Taylor J., Tyler A., Upadhyay S.K.Fuentes:scopus